事件2024 年，公司实现营业收入2576.73 亿元，同比+4.77%；归母净利润33.51亿元，同比-13.06%；扣非归母净利润33.51 亿元，同比-0.61%。归母净利润同比下滑主要系联营公司减值等一次性项目影响，剔除该影响后，2024年公司归母净利润同比稳健增长13.1%。三大分部业务增长稳健，制药业务毛利贡献突出按业务拆分，2024 年制药、医药分销、药品零售及其他三个主要业务分部的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.